Boston Scientific (BSX) said Friday that it completed the acquisition of Axonics (AXNX), a medical technology company specializing in devices for urinary and bowel dysfunction.
The company said the deal, which has an equity value of $3.7 billion and an enterprise value of $3.3 billion, is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and become accretive afterward.
Boston Scientific also said that the deal is slated to be less accretive on a GAAP basis due to amortization and acquisition-related costs.
Price: 87.12, Change: -0.47, Percent Change: -0.54
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。